John M Burke
John M Burke
President and CEO, Applied BioMath
Dirección de correo verificada de - Página principal
Citado por
Citado por
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
SL Spencer, S Gaudet, JG Albeck, JM Burke, PK Sorger
Nature 459 (7245), 428-432, 2009
Physicochemical modelling of cell signalling pathways
BB Aldridge, JM Burke, DA Lauffenburger, PK Sorger
Nature cell biology 8 (11), 1195-1203, 2006
Quantitative analysis of pathways controlling extrinsic apoptosis in single cells
JG Albeck, JM Burke, BB Aldridge, M Zhang, DA Lauffenburger, ...
Molecular cell 30 (1), 11-25, 2008
Modeling a snap-action, variable-delay switch controlling extrinsic cell death
JG Albeck, JM Burke, SL Spencer, DA Lauffenburger, PK Sorger
PLoS biology 6 (12), e299, 2008
Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks
DC Kirouac, J Saez-Rodriguez, J Swantek, JM Burke, DA Lauffenburger, ...
BMC systems biology 6 (1), 1-17, 2012
Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation
DS Jones, AP Jenney, JL Swantek, JM Burke, DA Lauffenburger, ...
Nature chemical biology 13 (1), 38-45, 2017
Systematic calibration of a cell signaling network model
K Kim, SL Spencer, JG Albeck, JM Burke, PK Sorger, S Gaudet, DH Kim
BMC bioinformatics 11 (1), 1-14, 2010
Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase …
BS Hendriks, J Cook, JM Burke, JM Beusmans, DA Lauffenburger, ...
IEE Proceedings-Systems Biology 153 (1), 22-33, 2006
Fibrinolytic therapy for refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific rationale and review
CD Barrett, HB Moore, EE Moore, RC McIntyre, PK Moore, J Burke, F Hua, ...
Research and Practice in Thrombosis and Haemostasis 4 (4), 524-531, 2020
Quantitative systems toxicology
P Bloomingdale, C Housand, JF Apgar, BL Millard, DE Mager, JM Burke, ...
Current opinion in toxicology 4, 79-87, 2017
Quantitative systems pharmacology model of hUGT1A1‐modRNA Encoding for the UGT1A1 enzyme to treat Crigler‐Najjar syndrome type 1
JF Apgar, JP Tang, P Singh, N Balasubramanian, J Burke, MR Hodges, ...
CPT: pharmacometrics & systems pharmacology 7 (6), 404-412, 2018
Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.
HA Burris, MK Callahan, AW Tolcher, S Kummar, GS Falchook, ...
Journal of Clinical Oncology 35 (15_suppl), 3033-3033, 2017
Quantitative systems pharmacology model of a masked, tumor‐activated antibody
M Stroh, J Sagert, JM Burke, JF Apgar, L Lin, BL Millard, WM Kavanaugh
CPT: pharmacometrics & systems pharmacology 8 (9), 676-684, 2019
Model‐Informed Drug Development of the Masked Anti‑PD‑L1 Antibody CX‐072
M Stroh, M Green, BL Millard, JF Apgar, JM Burke, W Garner, H Lu, ...
Clinical Pharmacology & Therapeutics 109 (2), 383-393, 2021
An introduction to the regulatory and nonclinical aspects of the nonclinical development of antibody drug conjugates
JA Lansita, JM Burke, JF Apgar, B Mounho-Zamora
Pharmaceutical research 32 (11), 3584-3592, 2015
CORRIGENDUM: Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1
JF Apgar, JP Tang, P Singh, N Balasubramanian, JM Burke, MR Hodges, ...
CPT: Pharmacometrics & Systems Pharmacology 9 (3), 185, 2020
A quantitative systems pharmacology model of colonic motility with applications in drug development
R Das, L Wille, L Zhang, C Chen, W Winchester, J Selimkhanov, ...
Journal of Pharmacokinetics and Pharmacodynamics 46 (5), 485-498, 2019
Inferring target occupancy from fitting nonlinear-PK data with mechanistic PKRO model for Pembrolizumab
F Hua, L Lin, L Gruenbaum, BL Millard, JM Burke, JF Apgar
Cancer Research 79 (13_Supplement), 4126-4126, 2019
Quantitative systems pharmacology modeling and analysis provides biological insights into anti-PD-1 dosing and predicts optimal PD-1 x TIM-3 therapeutic properties for …
J Apgar, J Wong, R Phennicie, R Mabry, T Novobrantseva, M Briskin, ...
Cancer Research 76 (14_Supplement), 5001-5001, 2016
Drug-induced TMDD: a novel class of PK models relevant to Immune-stimulating therapies
F Hua, D Flowers, DC Kirouac, JM Burke, JF Apgar
Cancer Research 79 (13_Supplement), 678-678, 2019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20